April 2017 VOL 8, NO 4


Letters from Lillie

AONN+ Initiatives Advance the Impact of Navigation

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Dear Navigators, We’re gearing up for our first meeting of 2017! The Academy of Oncology Nurse & Patient Navigators (AONN+) is venturing out west to Phoenix, AZ, this month to [ Read More ]

Interview with the Innovators

Navigation Collaborations: AONN+, Sarah Cannon, and the Cancer Moonshot Program

An Interview with Crystal Dugger, RN, BSN, MBA, of Sarah Cannon, the Cancer Institute of HCA

Sarah Cannon offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. It is nationally recognized for [ Read More ]

Original Research

Medication Adherence Among Patients with Chronic Myeloid Leukemia: The Impact of Financial Burden and Psychosocial Distress

Joanne S. Buzaglo, PhD1; Melissa F. Miller, PhD, MPH1; Clare Karten, MS1; Margaret L. Longacre, PhD1; Eberechukwu Onukwugha, MS, PhD2; Elisa S. Weiss, PhD3; Joseph A. Greer, PhD4; Mitch Golant, PhD1; Michael Mauro, MD5
1Cancer Support Community, Washington, DC;
2University of Maryland School of Pharmacy, Baltimore, MD;
3The Leukemia & Lymphoma Society, White Plains, NY;
4Massachusetts General Hospital Cancer Center, Boston, MA;
5Memorial Sloan Kettering Cancer Center, New York, NY

 

Background: Medication adherence is a key contributor to survival for patients with chronic myeloid leukemia (CML). About 25% to 35% of CML patients have been reported to have suboptimal medication [ Read More ]

What I Wish I Knew

What I Wish I Knew When I Was Diagnosed with Ovarian Cancer Responses from an Online Community

Roni Zeiger, MD
Cofounder and CEO
Smart Patients 

Recently, a member from the Smart Patients ovarian cancer community asked, “What do you wish you knew when you were first diagnosed?” The responses ran the emotional, social, and practical [ Read More ]

Navigator's Notebook

The Power of Navigation A Case Presentation

Suzanne Schupp, MSN, MAT, RN 

In early fall 2016, I was referred to a newly diagnosed breast cancer patient I will call “Teresa.” Teresa is a retired professional in her early 60s; she is divorced. [ Read More ]

2017 Genitourinary Cancers Symposium

Evidence Supports Active Surveillance for Small Renal Masses

Active surveillance is gaining ground as a strategy for managing small renal masses. According to intermediate follow-up of the prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry, [ Read More ]

2017 Genitourinary Cancers Symposium

Atezolizumab/Bevacizumab Combo Looks Promising in Metastatic Kidney Cancer

Atezolizumab plus bevacizumab showed encouraging responses as a first-line approach to treatment of metastatic renal cell carcinoma (mRCC) in a phase 2 trial. Although the trial failed to meet its [ Read More ]

2017 Genitourinary Cancers Symposium

Patients’ Expectations of Treatment off Target

Despite consultations with oncologists about the goal of treatment, more than one-third of men with incurable prostate cancer believed that a cure was possible with the treatments they were about [ Read More ]

2017 Genitourinary Cancers Symposium

Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome

Starting at a low dose of sorafenib and titrating up to the full dose of 800 mg, rather than starting at the full dose, does not adversely affect outcomes and [ Read More ]

2017 Genitourinary Cancers Symposium

Concurrent EGFR and BRAF Inhibition Improves PFS in BRAF V600 Mutation–Positive Colorectal Cancer

Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC). The median PFS was extended [ Read More ]

2017 Genitourinary Cancers Symposium

Cabozantinib Active in Advanced Neuroendocrine Tumors

The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib demonstrated encouraging activity in patients with advanced neuroendocrine tumors (NETs), including patients previously treated with sunitinib or everolimus, a preliminary clinical study showed. [ Read More ]

American Psychosocial Oncology Society

It Might Not Be Burnout: Recognizing Compassion Fatigue and Building Resilience

Constant exposure to patient distress and trauma can take a toll on oncology workers, and it often leads to a phenomenon called secondary traumatic stress, or “compassion fatigue,” according to [ Read More ]

2017 Cancer Survivorship Symposium

Rapid Adoption of Novel Oncology Therapies Improves Overall Survival

Innovation takes time, especially when it comes to cancer research. Unfortunately, delays in the adoption of novel oncology treatments can have a significant effect on patient health. Geographic analysis of [ Read More ]

The Round Table: Insight From Expert Navigators

Personalized Medicines Now Account for Nearly 1 in 4 New Drug Approvals

Daryl Pritchard, PhD; Vice President, Science Policy; Personalized Medicine Coalition 

If new drug approvals are any indication, personalized medicine will be a significant part of oncology navigation in the coming years. The FDA’s Center for Drug Evaluation and Research approved [ Read More ]